Fu Aigen's team at Northwestern University revealed the molecular mechanism of Chlamydomonas reinin's resistance to bright light
Time of Update: 2023-01-01
Recently, Professor Fu Aigen of Northwest University published a report entitled "Immunophilin CYN28 is required for accumulation of photosystem II and thylakoid FtsH protease in Chlamydomonas" online in Plant Physiology The paper is the first to report a molecular mechanism by which the pro-immune protein CYN28, localized in the thylakoid lumen, is involved in Chlamydomonas against high light.
But the PK drug king, Xiumeile, a new drug for psoriasis, has been approved for marketing, and the domestic same case sold for only 30 million yuan. It was once praised as the "diamond standard
Time of Update: 2022-08-15
The Chinese pharmaceutical field has long been eager for FIC, but when we discover FIC, how will we face it? If the FDA hadn't approved the drug, this FIC drug with deep roots in China might have bee
Changzhi City, Shanxi Actively Carrying Out the Rectification of the Pesticide Market
Time of Update: 2022-02-28
In order to standardize and strengthen the management of the city’s pesticide market, publicize and implement the newly revised "Regulations on Pesticide Management", the Municipal Agriculture Committee has recently organized and carried out a special pesticide management action in the city, using the "double random and one open" supervision model to monitor farmers in all counties, cities, and districts.
"Top Student" LOXO-435 Among FGFR3 Inhibitors
Time of Update: 2022-01-26
LOXO-435 exhibits a broad therapeutic index in vivo Preclinical data for LOXO-435Preclinical data for LOXO-435The kinase profile data in Figure 7 and subsequent data demonstrating the safety of the compound demonstrate that LOXO-435 is a potent, highly isoform-selective FGFR3 inhibitor with potency against FGFR3 gatekeeper resistance mutations; LOXO -435 can avoid the dose-limiting toxicity caused by inhibition of FGFR1 and FGFR2 - hyperphosphatemia and other adverse events of chronic intolerance .
Children with short stature are no longer "without medicine", and the first "dwarfism growth and development drug" has been approved by the FDA for marketing
Time of Update: 2021-12-05
S. Food and Drug Administration (FDA) approved the injectable preparation Voxzogo for use in children with "open" achondroplasia (growth plates) 5 years of age and older .
Achondroplasia is the most common cause of dwarfism, and the approval of the drug means that these children are still likely to grow taller .
Chinese scholars have made progress in the formation mechanism of natural hydrogen
Time of Update: 2021-10-11
Figure 1 Ni 2+ promotes Fe(OH) 2 oxidation to produce hydrogen and its mechanism schematic diagram Supported by the National Natural Science Foundation of China (Project Approval Number:
The Model Organism Dictyostelium discoideum
Time of Update: 2021-02-18
discoideum is a newcomer, yet it has proven to be a powerful genetic and cellular model for investigating host–pathogen interactions and microbial infections, for mitochondrial diseases, and for pharmacogenetic studies.
The opportunities offered by the organism and its place among the nonmammalian models for human diseases will be discussed.
Soy isoflavones can improve memory damage caused by chronic sleep disorders
Time of Update: 2020-12-30
Recently, the Agricultural Nutrition and Functional Factors Of the Agricultural Processing Research Institute of the Chinese Academy of Agricultural Sciences made a breakthrough by using the soybean isoflavone as the research object, using the chronic sleep disturbance mouse model to evaluate the puzzle efficacy of soybean isoflavone and explore its mechanism of action.
Lu Wenwei Associate Researcher: Roy's Lactobacillus CCFM1072 and C CFM1040 with Treg cell regulation regulate allergies
Time of Update: 2020-12-22
the Roy's Lactobacillus C CFM1072 and C CFM1040 strains increased the number of Tregs in the spleen, reduced airway inflammation, lowered histamine, IL-17A, IL-5, and IL-13 levels in the lungs, and reduced the concentration of Th2-related immunoglobulins in the serum.
Nature: Scientists have analyzed 97,691 genomes to reveal the genetic causes of the cloning process
Time of Update: 2020-11-02
October 19, 2020 // -- Scientists from Massachusetts General Hospital and other institutions have revealed the genetic causes of clone-induced hematopoiesis by analyzing the entire genome of 97,691 in
These varieties require careful consideration of volume procurement
Time of Update: 2020-10-22
To a certain extent, the national level of the volume of procurement, is the use of domestic generic drugs that have passed the consistent evaluation of the lowest price or the standard reduction of the winning bid, the corresponding product regulations of multinational enterprises to achieve clinical substitution of the original research drugs.
Healing Alzheimer's! FDA grants AXS-05 breakthrough drug eligibility
Time of Update: 2020-10-21
clinical studies have shown that AXS-05 can rapidly, substantially, and significantly improve the progression of AD patients compared to placebos.
AXS-05 is a new, oral, proprietary NMDA subject antagonist with multi-mode activity and is currently being clinically developed to treat depression and other central nervous system (CNS) diseases.
PNAS: Long-acting drugs help treat HIV
Time of Update: 2020-09-29
addition, drug resistance has been a challenge because HIV often mutates, so researchers have been looking for new drugs with novel mechanisms to produce more effective combination therapies.
the new study, researchers tested a unique drug called CPT31, which targets key structures in the HIV fusion mechanism with few mutations.
Rincazole is being studied for anti-cancer treatment
Time of Update: 2020-07-04
Modern Biosciences has begun new research as a possible cancer drug, the former schizophrenia drug rimazole has announced Anti-cancer studies of rincazole focused on sigma-1 receptors The receptor
Gene Tektronix's new heavy flu drug Baloxavir marboxil's Phase 3 study CAPSTONE-2 reaches its main destination
Time of Update: 2020-06-11
today, Genentech, a member of the Roche Group, announced that the , a new drug to assess the efficacy of a new drug heavy influenza, reached its main destination in the phase 3 study CAPSTONE-2, wh